Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE 3: Once-weekly IcoSema vs once-daily insulin glargine (with insulin aspart) in type 2 diabetes
jRCT2051210127Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2021
- Modality
- Peptides
01
Overview
Randomised trial of icosema in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to week 52. Started Nov 2021; status: completed.
02
Drugs
icosema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2051210127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210127.